Ann: Alterity to present at GCFF Virtual Conference 2022, page-6

From what I remember, ATH has had earlier a patent for PBT2 in cardiac light chain amyloidosis, it is usually mentioned in the annual report. Now, if I understand this correctly, the new patent is for "immunoglobulin light chain amyloidosis" and cardiac light chain amyloidosis is only a part of this. I post here a brand new about light chain amyloidosis. The only PBT2 paper in this field is this: Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage - PubMed (nih.gov). It was done with an Italian group and Dr. Robert Cherny from Prana.

Here you can find the review if you are interested in light-chain amyloidosis: IJMS | Free Full-Text | Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis | HTML (mdpi.com).

It is interesting that there are no scientific papers published about this. We do not know if the drug is PBT2 or ATH434, both are metal chelators. i would think that the drug is PBT2, but it could be also ATH434 or another metal chelator.